Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity.

Su YL, Banerjee S, White SV, Kortylewski M.

Int J Mol Sci. 2018 Jun 19;19(6). pii: E1803. doi: 10.3390/ijms19061803. Review.

2.

SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function.

Skrzypek K, Kusienicka A, Trzyna E, Szewczyk B, Ulman A, Konieczny P, Adamus T, Badyra B, Kortylewski M, Majka M.

Cell Death Dis. 2018 May 29;9(6):643. doi: 10.1038/s41419-018-0693-8.

3.

The revival of CpG oligonucleotide-based cancer immunotherapies.

Adamus T, Kortylewski M.

Contemp Oncol (Pozn). 2018 Mar;22(1A):56-60. doi: 10.5114/wo.2018.73887. Epub 2018 Mar 5. Review.

4.

Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients.

Sampath S, Won H, Massarelli E, Li M, Frankel P, Vora N, Vora L, Maghami E, Kortylewski M.

Oncotarget. 2018 Feb 2;9(13):11279-11290. doi: 10.18632/oncotarget.24397. eCollection 2018 Feb 16.

5.

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.

Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G.

Nat Med. 2018 May;24(4):450-462. doi: 10.1038/nm.4499. Epub 2018 Mar 5.

PMID:
29505034
6.

B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.

Zhao X, Zhang Z, Moreira D, Su YL, Won H, Adamus T, Dong Z, Liang Y, Yin HH, Swiderski P, Pillai RK, Kwak L, Forman S, Kortylewski M.

Mol Ther. 2018 Mar 7;26(3):695-707. doi: 10.1016/j.ymthe.2018.01.007. Epub 2018 Jan 17.

7.

Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.

Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO.

Urol Oncol. 2018 Apr;36(4):162.e1-162.e6. doi: 10.1016/j.urolonc.2017.12.006. Epub 2017 Dec 27.

PMID:
29289429
8.

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).

Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO.

Cancer. 2018 Mar 15;124(6):1216-1224. doi: 10.1002/cncr.31161. Epub 2017 Dec 19.

PMID:
29266182
9.

Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.

Kozlowska AK, Florczak A, Smialek M, Dondajewska E, Mackiewicz A, Kortylewski M, Dams-Kozlowska H.

Acta Biomater. 2017 Sep 1;59:221-233. doi: 10.1016/j.actbio.2017.07.014. Epub 2017 Jul 8.

PMID:
28694238
10.

TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.

Won H, Moreira D, Gao C, Duttagupta P, Zhao X, Manuel E, Diamond D, Yuan YC, Liu Z, Jones J, D'Apuzzo M, Pal S, Kortylewski M.

J Leukoc Biol. 2017 Aug;102(2):423-436. doi: 10.1189/jlb.3MA1016-451RR. Epub 2017 May 22.

11.

Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Kortylewski M, Moreira D.

Cancer Immunol Immunother. 2017 Aug;66(8):979-988. doi: 10.1007/s00262-017-1966-2. Epub 2017 Feb 18. Review.

12.

STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.

Curran E, Chen X, Corrales L, Kline DE, Dubensky TW Jr, Duttagupta P, Kortylewski M, Kline J.

Cell Rep. 2016 Jun 14;15(11):2357-66. doi: 10.1016/j.celrep.2016.05.023. Epub 2016 Jun 2.

13.

Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer.

Pal SK, Kortylewski M.

Oncoimmunology. 2015 Aug 24;5(2):e1078060. eCollection 2016 Feb.

14.

Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.

Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, Buettner R, Nechaev S, Majka M, Zhang B, Cai Q, Swiderski P, Kuo YH, Forman S, Marcucci G, Kortylewski M.

Blood. 2016 Mar 31;127(13):1687-700. doi: 10.1182/blood-2015-08-665604. Epub 2016 Jan 21.

15.

TLR9-Targeted SiRNA Delivery In Vivo.

Hossain DM, Moreira D, Zhang Q, Nechaev S, Swiderski P, Kortylewski M.

Methods Mol Biol. 2016;1364:183-96. doi: 10.1007/978-1-4939-3112-5_15.

16.

Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors.

Pal SK, Li SM, Wu X, Qin H, Kortylewski M, Hsu J, Carmichael C, Frankel P.

Clin Cancer Res. 2015 Dec 1;21(23):5286-93. doi: 10.1158/1078-0432.CCR-15-0724. Epub 2015 Jul 7.

17.

TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.

Moreira D, Zhang Q, Hossain DM, Nechaev S, Li H, Kowolik CM, D'Apuzzo M, Forman S, Jones J, Pal SK, Kortylewski M.

Oncotarget. 2015 Jul 10;6(19):17302-13.

18.

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H.

J Clin Invest. 2015 Jun;125(6):2547. doi: 10.1172/JCI82555. Epub 2015 Jun 1. No abstract available.

19.

TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, Jones J, D'Apuzzo M, Forman S, Kortylewski M.

Clin Cancer Res. 2015 Aug 15;21(16):3771-82. doi: 10.1158/1078-0432.CCR-14-3145. Epub 2015 May 12.

20.

The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy.

Sakib Hossain DM, Duttagupta P, Kortylewski M.

Ther Deliv. 2015 Jan;6(1):1-4. doi: 10.4155/tde.14.92. No abstract available.

21.

The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy.

Kortylewski M, Pal SK.

Oncoimmunology. 2014 Feb 14;3:e27894. eCollection 2014.

22.

Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.

Pal SK, Hossain DM, Zhang Q, Frankel PH, Jones JO, Carmichael C, Ruel C, Lau C, Kortylewski M.

J Urol. 2015 Apr;193(4):1114-21. doi: 10.1016/j.juro.2014.09.110. Epub 2014 Oct 5.

PMID:
25286010
23.

TLR9 is critical for glioma stem cell maintenance and targeting.

Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, Wang T, Lee H, Lahtz C, Swiderski P, Armstrong B, Kowolik C, Gallia GL, Lim M, Brown C, Badie B, Forman S, Kortylewski M, Jove R, Yu H.

Cancer Res. 2014 Sep 15;74(18):5218-28. doi: 10.1158/0008-5472.CAN-14-1151. Epub 2014 Jul 21.

24.

Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-κB.

Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, Chin AR, Ren X, Gugiu BG, Meng Z, Huang W, Ngo V, Kortylewski M, Wang SE.

Sci Rep. 2014 Jul 18;4:5750. doi: 10.1038/srep05750.

25.

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H.

J Clin Invest. 2014 Jul;124(7):2977-87. doi: 10.1172/JCI73174. Epub 2014 Jun 2. Erratum in: J Clin Invest. 2015 Jun;125(6):2547. Swiderski, Piotr [Added].

26.

How to train your dragon: targeted delivery of microRNA to cancer cells in vivo.

Kortylewski M, Nechaev S.

Mol Ther. 2014 Jun;22(6):1070-1071. doi: 10.1038/mt.2014.73. No abstract available.

27.

Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.

Kortylewski M, Kuo YH.

Oncoimmunology. 2014 Jan 1;3(1):e27441. Epub 2014 Jan 3.

28.

Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?

Kortylewski M, Nechaev S.

Ther Deliv. 2014 Mar;5(3):239-42. doi: 10.4155/tde.13.152. No abstract available.

PMID:
24592948
29.

Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.

Hossain DM, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline J, Forman S, Bhatia R, Kuo YH, Kortylewski M.

Blood. 2014 Jan 2;123(1):15-25. doi: 10.1182/blood-2013-07-517987. Epub 2013 Oct 29.

30.

TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy.

Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain DM, Kowolik CM, Chu P, Swiderski P, Diamond DJ, Pal SK, Raubitschek A, Kortylewski M.

Cancer Res. 2013 Dec 15;73(24):7211-21. doi: 10.1158/0008-5472.CAN-13-1314. Epub 2013 Oct 23.

31.

Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape.

Nechaev S, Gao C, Moreira D, Swiderski P, Jozwiak A, Kowolik CM, Zhou J, Armstrong B, Raubitschek A, Rossi JJ, Kortylewski M.

J Control Release. 2013 Sep 28;170(3):307-15. doi: 10.1016/j.jconrel.2013.06.007. Epub 2013 Jun 15.

32.

TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Zhang Q, Hossain DM, Nechaev S, Kozlowska A, Zhang W, Liu Y, Kowolik CM, Swiderski P, Rossi JJ, Forman S, Pal S, Bhatia R, Raubitschek A, Yu H, Kortylewski M.

Blood. 2013 Feb 21;121(8):1304-15. doi: 10.1182/blood-2012-07-442590. Epub 2013 Jan 3.

33.

Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

Ma Y, Kowolik CM, Swiderski PM, Kortylewski M, Yu H, Horne DA, Jove R, Caballero OL, Simpson AJ, Lee FT, Pillay V, Scott AM.

ACS Chem Biol. 2011 Sep 16;6(9):962-70. doi: 10.1021/cb200176v. Epub 2011 Jul 26.

34.

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.

Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, Jove R, Yu H.

Nat Med. 2010 Dec;16(12):1421-8. doi: 10.1038/nm.2250. Epub 2010 Nov 21.

35.

Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Pal SK, Kortylewski M, Yu H, Figlin RA.

Mol Cancer Ther. 2010 Dec;9(12):3115-25. doi: 10.1158/1535-7163.MCT-10-0873. Epub 2010 Nov 15. Review.

36.

Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells.

Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, Wang L, Kowolik C, Deng J, Figlin R, Yu H.

Cancer Res. 2010 Oct 1;70(19):7455-64. doi: 10.1158/0008-5472.CAN-10-0736. Epub 2010 Sep 14.

37.

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H.

Nat Biotechnol. 2009 Oct;27(10):925-32. doi: 10.1038/nbt.1564. Epub 2009 Sep 13.

38.

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway.

Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H.

J Exp Med. 2009 Jul 6;206(7):1457-64. doi: 10.1084/jem.20090207. Epub 2009 Jun 29.

39.

Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice.

Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B.

Glia. 2009 Oct;57(13):1458-67. doi: 10.1002/glia.20863.

PMID:
19306372
40.

Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy.

Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, Salcedo R, Yu H.

Cancer Res. 2009 Mar 15;69(6):2497-505. doi: 10.1158/0008-5472.CAN-08-3031. Epub 2009 Mar 3.

41.

Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H.

Cancer Cell. 2009 Feb 3;15(2):114-23. doi: 10.1016/j.ccr.2008.12.018. Erratum in: Cancer Cell. 2010 Nov 16;18(5):536.

42.

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.

Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H.

J Clin Invest. 2008 Oct;118(10):3367-77. doi: 10.1172/JCI35213.

43.

Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells.

Niu G, Briggs J, Deng J, Ma Y, Lee H, Kortylewski M, Kujawski M, Kay H, Cress WD, Jove R, Yu H.

Mol Cancer Res. 2008 Jul;6(7):1099-105. doi: 10.1158/1541-7786.MCR-07-2177.

44.

Role of Stat3 in suppressing anti-tumor immunity.

Kortylewski M, Yu H.

Curr Opin Immunol. 2008 Apr;20(2):228-33. doi: 10.1016/j.coi.2008.03.010. Epub 2008 May 12. Review.

45.

Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.

Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, Housseau F, Yu H, Pardoll DM, Drake CG.

J Immunol. 2007 Oct 1;179(7):4313-7.

46.

Stat3 as a potential target for cancer immunotherapy.

Kortylewski M, Yu H.

J Immunother. 2007 Feb-Mar;30(2):131-9. Review.

PMID:
17471161
47.

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Yu H, Kortylewski M, Pardoll D.

Nat Rev Immunol. 2007 Jan;7(1):41-51. Review.

PMID:
17186030
48.

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R, Pardoll D, Yu H.

Nat Med. 2005 Dec;11(12):1314-21. Epub 2005 Nov 20.

PMID:
16288283
49.

STAT5 contributes to interferon resistance of melanoma cells.

Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, Behrmann I, Kortylewski M, Heinrich PC, Schartl M.

Curr Biol. 2005 Sep 20;15(18):1629-39.

50.

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.

Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, Yu H.

Oncogene. 2005 Aug 25;24(36):5552-60.

PMID:
16007214

Supplemental Content

Loading ...
Support Center